All In Biotech

Drug Trial Radar · NCT07884136

RBD1119 in Coronary Artery Disease (CAD)

A Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants With CAD

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Sep 30, 2027

Study completion Mar 18, 2028

Sponsor

Lead sponsor
Ribocure Pharmaceuticals ABIndustry
Sponsor type
Industry
Collaborators
Fortrea
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death. Despite contemporary secondary prevention including lipid lowering, revascularization when indicated, and antiplatelet therapy, participants with established CAD, particularly those post-ACS, remain at clinically meaningful residual risk of recurrent atherothrombotic events. Intensifying antithrombotic therapy can reduce ischemic events but typically increases bleeding, as exemplified by the addition of low dose rivaroxaban to aspirin in stable atherosclerotic disease. This persistent efficacy-safety trade-off supports development of antithrombotic approaches that reduce pathological thrombosis while preserving hemostasis. RBD1119 is a GalNAc-conjugated siRNA that targets factor XI mRNA in hepatocytes. The GalNAc moiety binds the asialoglycoprotein receptor on hepatocyte surfaces, enabling receptor mediated endocytosis and preferential hepatic uptake. Once internalized, RBD1119 mediates cleavage of factor XI mRNA via the RNA interference pathway, reducing hepatic factor XI expression and lowering circulating factor XI levels. This multicenter, randomized, double-blind, placebo-controlled, phase II trial will evaluate the PD, safety, and PK of subcutaneously administered RBD1119 in participants with stable coronary artery disease (CAD).

Conditions

  • Stable Coronary Artery Disease

Interventions

  • RBD1119Drug

    RBD1119, active drug

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary objectiveTime frame: Week 8
  2. Primary endpointTime frame: Week 8

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Gabinet Kardiologiczno-Internistyczny

    Gdynia, Poland

  • Cardiology Department, SPS Szpital Zachodni im św Jana Pawła II

    Grodzisk Mazowiecki, Poland

  • Centrum Medyczne Vitamedicum itw

    Krakow, Poland

  • Specjalistyczna Praktyka Lekarska Ewa Mirek Bryniarska

    Krakow, Poland

  • Department of Cardiology, The Copper Health Centre MCZ

    Lubin, Poland

  • Velocity Nova Sp. z o.o. site: Velocity Lublin

    Lublin, Poland

  • balsam MEDICA medical centre

    Warsaw, Poland

  • Centrum Medyczne LUX MED (LUX MED Sp. z o.o.)

    Warsaw, Poland

  • Klinika Sienna

    Warsaw, Poland

  • Przychodnia Care Access Warszawa

    Warsaw, Poland

  • Velocity Nova Sp. z o.o. site: Velocity Zamość

    Zamość, Poland

  • Kardiologi VO Hjärt- och lungmedicin

    Lund, Sweden

  • Ribocure Clinic

    Mölndal, Sweden

  • Örebro University Hospital

    Örebro, Sweden

  • Dalecarlia Clinical Research Center

    Rättvik, Sweden

  • Clinical Trial Consultants Stockholm

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.